Shelley Thunen Adds to LENZ Holdings
Shelley Thunen acquired 22,100 shares of LENZ on June 15, 2026.
Key Points
- Shelley Thunen bought 22,100 shares of LENZ on June 15, 2026, as the stock trades at $6.77.
- LENZ has seen varied institutional activity, with Versant Venture Management doubling its stake by adding 2.66 million shares.
- Analysts from Citigroup and HC Wainwright & Co. maintain a 'buy' rating, with price targets up to $38.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Shelley Thunen, an insider at LENZ, purchased 22,100 shares of the company on June 15, 2026. The stock is currently trading at $6.77. This transaction is not part of a pre-planned trading program.
Other Institutional Activity in LENZ
LENZ has been the focus of various institutional investors. Versant Venture Management, LLC significantly increased its position by adding 2,656,888 shares, bringing its total to 5,313,776 shares valued at approximately $48.6 million. Meanwhile, RA Capital Management, L.P. maintained its stake at 4,178,823 shares, worth about $38.2 million. Alpha Wave Global, LP also kept its holdings unchanged at 3,612,211 shares, valued at $33.1 million. FMR LLC slightly reduced its position by 104,934 shares, resulting in a total of 3,597,784 shares worth $32.9 million. BlackRock, Inc. increased its holdings by 284,817 shares, reaching a total of 1,976,823 shares valued at $18.1 million.
Insider Buying and Selling at LENZ Therapeutics, Inc.
On June 15, 2026, several insiders at LENZ made similar purchases. Zachary Scheiner, Frederic Guerard, James McCollum, Shelley Thunen, Kimberlee Drapkin, and Jeffrey George each acquired 22,100 shares. These transactions were not part of pre-planned trading programs.
Analysts Set New Price Targets
Analyst firms have been active in updating their perspectives on LENZ. On May 13, 2026, Citigroup maintained its 'buy' rating with a $20 price target. HC Wainwright & Co. also held its 'buy' rating with a $38 target on May 12, 2026. However, Piper Sandler downgraded the stock to 'hold' and set a $12 target on the same day. Overall, the consensus remains positive, with a 'buy' recommendation and an average price target reflecting optimism among analysts.
Bottom Line
Shelley Thunen's recent purchase of LENZ shares adds to a series of insider transactions, reflecting some confidence in the company's prospects. Institutional investors have shown mixed actions, with some increasing their stakes significantly. Analysts continue to view LENZ favorably, maintaining high price targets. As always, it's important to remember that insider transactions and analyst ratings are just pieces of the broader investment puzzle.
Get LENZ Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $LENZ, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.